全文获取类型
收费全文 | 11762篇 |
免费 | 1026篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 230篇 |
儿科学 | 331篇 |
妇产科学 | 158篇 |
基础医学 | 1371篇 |
口腔科学 | 225篇 |
临床医学 | 1233篇 |
内科学 | 2343篇 |
皮肤病学 | 169篇 |
神经病学 | 1427篇 |
特种医学 | 455篇 |
外科学 | 1424篇 |
综合类 | 367篇 |
一般理论 | 3篇 |
预防医学 | 1106篇 |
眼科学 | 237篇 |
药学 | 896篇 |
中国医学 | 6篇 |
肿瘤学 | 857篇 |
出版年
2021年 | 95篇 |
2020年 | 102篇 |
2019年 | 155篇 |
2018年 | 186篇 |
2017年 | 136篇 |
2016年 | 157篇 |
2015年 | 192篇 |
2014年 | 268篇 |
2013年 | 445篇 |
2012年 | 594篇 |
2011年 | 611篇 |
2010年 | 362篇 |
2009年 | 314篇 |
2008年 | 549篇 |
2007年 | 643篇 |
2006年 | 548篇 |
2005年 | 601篇 |
2004年 | 595篇 |
2003年 | 564篇 |
2002年 | 500篇 |
2001年 | 237篇 |
2000年 | 244篇 |
1999年 | 224篇 |
1998年 | 182篇 |
1997年 | 142篇 |
1996年 | 137篇 |
1995年 | 128篇 |
1994年 | 123篇 |
1993年 | 130篇 |
1992年 | 202篇 |
1991年 | 195篇 |
1990年 | 171篇 |
1989年 | 160篇 |
1988年 | 163篇 |
1987年 | 186篇 |
1986年 | 153篇 |
1985年 | 175篇 |
1984年 | 182篇 |
1983年 | 162篇 |
1982年 | 165篇 |
1981年 | 150篇 |
1980年 | 120篇 |
1979年 | 117篇 |
1978年 | 145篇 |
1977年 | 104篇 |
1976年 | 117篇 |
1975年 | 116篇 |
1974年 | 95篇 |
1973年 | 76篇 |
1968年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Arthur Winer Crystal S. Denlinger Namrata Vijayvergia Steven J. Cohen Igor Astaturov Efrat Dotan Jean-Nicolas Gallant Edward W. Wang Miriam Kunkel Bora Lim Harold A. Harvey Jeffrey Sivik Kenneth Korzekwa Karen Ruth Kevin White Harry S. Cooper Eric A. Ross Lanlan Zhou Wafik S. El-Deiry 《Clinical colorectal cancer》2021,20(1):e43-e52
BackgroundQuinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC.Patients and MethodsUsing a modified Simon accelerated titration design, adults with treatment-refractory mCRC were treated with capecitabine 1000 mg/m2 twice daily for 14/21-day cycle, and escalating doses of quinacrine 100 mg daily, 100 mg twice daily, and 200 mg twice daily for 21 days. The primary endpoint was identifying the maximum tolerated dose, determining tolerability and safety. In an expansion cohort, it was overall response rate and time to tumor progression (TTP).ResultsTen patients (median age of 60 years) were treated in phase 1b. The first 2 quinacrine dosing levels were well tolerated. Dose-limiting toxicities were seen in 3 patients treated with quinacrine 200 mg twice daily. Five additional patients tolerated quinacrine 100 mg twice daily without further dose-limiting toxicities, thus establishing the maximum tolerated dose. Seven additional expansion-cohort patients enrolled onto the study before quinacrine manufacturing ceased within the United States. Five patients experienced stable disease, 1 partial response, and 10 disease progression. Median TTP overall was 2.12 months and median overall survival 5.22 months for the 17 patients.ConclusionCapecitabine and quinacrine can be safely administered at the maximum tolerated dose of capecitabine 1000 mg/m2 by mouth twice daily on days 1-14 and quinacrine 100 mg by mouth twice daily on days 1-21 of a 21-day cycle in mCRC patients. Although the expansion study was halted early, TTP was in line with other studies of refractory mCRC, suggesting activity of this regimen in heavily pretreated patients. 相似文献
4.
Todd C. Villines Subhi J. Al’Aref Daniele Andreini Marcus Y. Chen Andrew D. Choi Carlo N. De Cecco Damini Dey James P. Earls Maros Ferencik Heidi Gransar Harvey Hecht Jonathon A. Leipsic Michael T. Lu Mohamed Marwan Pál Maurovich-Horvat Edward Nicol Gianluca Pontone Jonathan Weir-McCall Gudrun M. Feuchtner 《Journal of Cardiovascular Computed Tomography》2021,15(2):180-189
5.
Nicholas C Harvey John A Kanis Enwu Liu Cyrus Cooper Mattias Lorentzon Jennifer W Bea Laura Carbone Elizabeth M Cespedes Feliciano Deepika R Laddu Peter F Schnatz Aladdin H Shadyab Marcia L Stefanick Jean Wactawski-Wende Carolyn J Crandall Helena Johansson Eugene McCloskey 《Journal of bone and mineral research》2021,36(4):654-661
In the Women's Health Initiative (WHI), we investigated associations between baseline dual-energy X-ray absorptiometry (DXA) appendicular lean mass (ALM) and risk of incident fractures, falls, and mortality (separately for each outcome) among older postmenopausal women, accounting for bone mineral density (BMD), prior falls, and Fracture Risk Assessment Tool (FRAX®) probability. The WHI is a prospective study of postmenopausal women undertaken at 40 US sites. We used an extension of Poisson regression to investigate the relationship between baseline ALM (corrected for height2) and incident fracture outcomes, presented here for major osteoporotic fracture (MOF: hip, clinical vertebral, forearm, or proximal humerus), falls, and death. Associations were adjusted for age, time since baseline and randomization group, or additionally for femoral neck (FN) BMD, prior falls, or FRAX probability (MOF without BMD) and are reported as gradient of risk (GR: hazard ratio for first incident fracture per SD increment) in ALM/height2 (GR). Data were available for 11,187 women (mean [SD] age 63.3 [7.4] years). In the base models (adjusted for age, follow-up time, and randomization group), greater ALM/height2 was associated with lower risk of incident MOF (GR = 0.88; 95% confidence interval [CI] 0.83–0.94). The association was independent of prior falls but was attenuated by FRAX probability. Adjustment for FN BMD T-score led to attenuation and inversion of the risk relationship (GR = 1.06; 95% CI 0.98–1.14). There were no associations between ALM/height2 and incident falls. However, there was a 7% to 15% increase in risk of death during follow-up for each SD greater ALM/height2, depending on specific adjustment. In WHI, and consistent with our findings in older men (Osteoporotic Fractures in Men [MrOS] study cohorts), the predictive value of DXA-ALM for future clinical fracture is attenuated (and potentially inverted) after adjustment for femoral neck BMD T-score. However, intriguing positive, but modest, associations between ALM/height2 and mortality remain robust. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). 相似文献
6.
7.
8.
9.